Global Myelodysplastic Syndrome Market

Success! Thanks for contacting us. We will contact you soon

Myelodysplastic Syndrome Market Insights and Forecast to 2028 with COVID-19 Impact Analysis

Published Date : May 2022

Category : Pharmaceutical & Healthcare

Report Id : QYR 9029

Publisher Name : QY Research

Price : $4900

No of Pages : 127

Market Analysis and Insights: Global Myelodysplastic Syndrome Market

Due to the pandemic of COVID-19, the global Myelodysplastic Syndrome Market size is estimated to be worth US$ million in 2022 and is expected to reach the size of US$ million by 2028 growing at a CAGR of % during the forecast period. Fully considering the economic change by this health crisis, Alkylating Agents accounted for % of the global Myelodysplastic Syndrome Market in 2021 and is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to a % CAGR throughout this forecast period.

North America held a significant share of the global Myelodysplastic Syndrome Market market in 2021 and was valued at US$ million in 2021. It is estimated to grow with a CAGR of % during the forecast period of 2022-2028 and is estimated to reach US$ million by 2028.

China Myelodysplastic Syndrome Market size is valued at US$ million in 2021, while the US and Europe Myelodysplastic Syndrome Market are US$ million and US$ million, respectively. The share of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China’s share will reach % in 2028, trailing a CAGR of % through the forecast period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Myelodysplastic Syndrome Market landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

The global key manufacturers of Myelodysplastic Syndrome Market include Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Onconova Therapeutics, Strategia Therapeutics, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Astex, Celator Pharmaceuticals, Eli-lilly, Sunesis Pharmaceuticals, Targazyme, Gamida Cell, GlaxoSmithKline, Sumitomo Dainippon Pharma, TetraLogic Pharmaceuticals, , etc. In 2021, the global top five players have a share of approximately % in terms of revenue.

In terms of the production, this report researches the Myelodysplastic Syndrome Market capacity, production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.

In terms of the sales, this report focuses on the sales of Myelodysplastic Syndrome Market by region (region level and country level), by company, by Type and by Application from 2017 to 2022 and forecast to 2028.

Market Segments

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

COVID-19 Impact Analysis on Myelodysplastic Syndrome Market Market

The report highlights the effects of the outbreak of COVID-19 on the development of the Myelodysplastic Syndrome Market market across the globe. The authors studied the changes which affected the production/manufacturing, supply chain, consumption, and the demand/supply side. With the help of this report, the reader will get acquainted with the measures which helped the key industry players to get the Myelodysplastic Syndrome Market market back to the pre-covid levels.

Global Myelodysplastic Syndrome Market Market: Drivers and Restrains

The research report examines market trends, segments, applications, restraints and drivers which affect the global Myelodysplastic Syndrome Market market. This report covers the global market for production volume, production by region, and pricing analysis for each type from 2018 to 2028. Factors influencing market development are important because they may be used to design diverse strategies for capturing the lucrative opportunities that exist in the continuously growing industry. In addition, market expert opinions have been incorporated for a better knowledge of the market.

Myelodysplastic Syndrome market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Myelodysplastic Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
Alkylating Agents
Cytotoxic Antibiotics
Topoisomerase Inhibitors
Others

Segment by Application
Hospital
Clinic

By Company
Celgene
Novartis
Otsuka
Actinium Pharmaceuticals
Acceleron Pharma
Bellicum Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Onconova Therapeutics
Strategia Therapeutics
KaloBios Pharmaceuticals
Kiadis Pharma
Mirati Therapeutics
Astex
Celator Pharmaceuticals
Eli-lilly
Sunesis Pharmaceuticals
Targazyme
Gamida Cell
GlaxoSmithKline
Sumitomo Dainippon Pharma
TetraLogic Pharmaceuticals

By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Table of Contents
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Alkylating Agents
1.2.3 Cytotoxic Antibiotics
1.2.4 Topoisomerase Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome Market Perspective (2017-2028)
2.2 Myelodysplastic Syndrome Growth Trends by Region
2.2.1 Myelodysplastic Syndrome Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Myelodysplastic Syndrome Historic Market Size by Region (2017-2022)
2.2.3 Myelodysplastic Syndrome Forecasted Market Size by Region (2023-2028)
2.3 Myelodysplastic Syndrome Market Dynamics
2.3.1 Myelodysplastic Syndrome Industry Trends
2.3.2 Myelodysplastic Syndrome Market Drivers
2.3.3 Myelodysplastic Syndrome Market Challenges
2.3.4 Myelodysplastic Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome Players by Revenue (2017-2022)
3.1.2 Global Myelodysplastic Syndrome Revenue Market Share by Players (2017-2022)
3.2 Global Myelodysplastic Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome Revenue
3.4 Global Myelodysplastic Syndrome Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Revenue in 2021
3.5 Myelodysplastic Syndrome Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome Historic Market Size by Type (2017-2022)
4.2 Global Myelodysplastic Syndrome Forecasted Market Size by Type (2023-2028)
5 Myelodysplastic Syndrome Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome Historic Market Size by Application (2017-2022)
5.2 Global Myelodysplastic Syndrome Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Myelodysplastic Syndrome Market Size (2017-2028)
6.2 North America Myelodysplastic Syndrome Market Size by Type
6.2.1 North America Myelodysplastic Syndrome Market Size by Type (2017-2022)
6.2.2 North America Myelodysplastic Syndrome Market Size by Type (2023-2028)
6.2.3 North America Myelodysplastic Syndrome Market Share by Type (2017-2028)
6.3 North America Myelodysplastic Syndrome Market Size by Application
6.3.1 North America Myelodysplastic Syndrome Market Size by Application (2017-2022)
6.3.2 North America Myelodysplastic Syndrome Market Size by Application (2023-2028)
6.3.3 North America Myelodysplastic Syndrome Market Share by Application (2017-2028)
6.4 North America Myelodysplastic Syndrome Market Size by Country
6.4.1 North America Myelodysplastic Syndrome Market Size by Country (2017-2022)
6.4.2 North America Myelodysplastic Syndrome Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome Market Size (2017-2028)
7.2 Europe Myelodysplastic Syndrome Market Size by Type
7.2.1 Europe Myelodysplastic Syndrome Market Size by Type (2017-2022)
7.2.2 Europe Myelodysplastic Syndrome Market Size by Type (2023-2028)
7.2.3 Europe Myelodysplastic Syndrome Market Share by Type (2017-2028)
7.3 Europe Myelodysplastic Syndrome Market Size by Application
7.3.1 Europe Myelodysplastic Syndrome Market Size by Application (2017-2022)
7.3.2 Europe Myelodysplastic Syndrome Market Size by Application (2023-2028)
7.3.3 Europe Myelodysplastic Syndrome Market Share by Application (2017-2028)
7.4 Europe Myelodysplastic Syndrome Market Size by Country
7.4.1 Europe Myelodysplastic Syndrome Market Size by Country (2017-2022)
7.4.2 Europe Myelodysplastic Syndrome Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome Market Size (2017-2028)
8.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Type
8.2.1 Asia-Pacific Myelodysplastic Syndrome Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Myelodysplastic Syndrome Market Share by Type (2017-2028)
8.3 Asia-Pacific Myelodysplastic Syndrome Market Size by Application
8.3.1 Asia-Pacific Myelodysplastic Syndrome Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Myelodysplastic Syndrome Market Share by Application (2017-2028)
8.4 Asia-Pacific Myelodysplastic Syndrome Market Size by Region
8.4.1 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome Market Size (2017-2028)
9.2 Latin America Myelodysplastic Syndrome Market Size by Type
9.2.1 Latin America Myelodysplastic Syndrome Market Size by Type (2017-2022)
9.2.2 Latin America Myelodysplastic Syndrome Market Size by Type (2023-2028)
9.2.3 Latin America Myelodysplastic Syndrome Market Share by Type (2017-2028)
9.3 Latin America Myelodysplastic Syndrome Market Size by Application
9.3.1 Latin America Myelodysplastic Syndrome Market Size by Application (2017-2022)
9.3.2 Latin America Myelodysplastic Syndrome Market Size by Application (2023-2028)
9.3.3 Latin America Myelodysplastic Syndrome Market Share by Application (2017-2028)
9.4 Latin America Myelodysplastic Syndrome Market Size by Country
9.4.1 Latin America Myelodysplastic Syndrome Market Size by Country (2017-2022)
9.4.2 Latin America Myelodysplastic Syndrome Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome Market Size (2017-2028)
10.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Type
10.2.1 Middle East & Africa Myelodysplastic Syndrome Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Myelodysplastic Syndrome Market Share by Type (2017-2028)
10.3 Middle East & Africa Myelodysplastic Syndrome Market Size by Application
10.3.1 Middle East & Africa Myelodysplastic Syndrome Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Myelodysplastic Syndrome Market Share by Application (2017-2028)
10.4 Middle East & Africa Myelodysplastic Syndrome Market Size by Country
10.4.1 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Details
11.1.2 Celgene Business Overview
11.1.3 Celgene Myelodysplastic Syndrome Introduction
11.1.4 Celgene Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.1.5 Celgene Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Myelodysplastic Syndrome Introduction
11.2.4 Novartis Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.2.5 Novartis Recent Developments
11.3 Otsuka
11.3.1 Otsuka Company Details
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Myelodysplastic Syndrome Introduction
11.3.4 Otsuka Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.3.5 Otsuka Recent Developments
11.4 Actinium Pharmaceuticals
11.4.1 Actinium Pharmaceuticals Company Details
11.4.2 Actinium Pharmaceuticals Business Overview
11.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Introduction
11.4.4 Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.4.5 Actinium Pharmaceuticals Recent Developments
11.5 Acceleron Pharma
11.5.1 Acceleron Pharma Company Details
11.5.2 Acceleron Pharma Business Overview
11.5.3 Acceleron Pharma Myelodysplastic Syndrome Introduction
11.5.4 Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.5.5 Acceleron Pharma Recent Developments
11.6 Bellicum Pharmaceuticals
11.6.1 Bellicum Pharmaceuticals Company Details
11.6.2 Bellicum Pharmaceuticals Business Overview
11.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Introduction
11.6.4 Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.6.5 Bellicum Pharmaceuticals Recent Developments
11.7 Cornerstone Pharmaceuticals
11.7.1 Cornerstone Pharmaceuticals Company Details
11.7.2 Cornerstone Pharmaceuticals Business Overview
11.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Introduction
11.7.4 Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.7.5 Cornerstone Pharmaceuticals Recent Developments
11.8 CTI BioPharma
11.8.1 CTI BioPharma Company Details
11.8.2 CTI BioPharma Business Overview
11.8.3 CTI BioPharma Myelodysplastic Syndrome Introduction
11.8.4 CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.8.5 CTI BioPharma Recent Developments
11.9 Onconova Therapeutics
11.9.1 Onconova Therapeutics Company Details
11.9.2 Onconova Therapeutics Business Overview
11.9.3 Onconova Therapeutics Myelodysplastic Syndrome Introduction
11.9.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.9.5 Onconova Therapeutics Recent Developments
11.10 Strategia Therapeutics
11.10.1 Strategia Therapeutics Company Details
11.10.2 Strategia Therapeutics Business Overview
11.10.3 Strategia Therapeutics Myelodysplastic Syndrome Introduction
11.10.4 Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.10.5 Strategia Therapeutics Recent Developments
11.11 KaloBios Pharmaceuticals
11.11.1 KaloBios Pharmaceuticals Company Details
11.11.2 KaloBios Pharmaceuticals Business Overview
11.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Introduction
11.11.4 KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.11.5 KaloBios Pharmaceuticals Recent Developments
11.12 Kiadis Pharma
11.12.1 Kiadis Pharma Company Details
11.12.2 Kiadis Pharma Business Overview
11.12.3 Kiadis Pharma Myelodysplastic Syndrome Introduction
11.12.4 Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.12.5 Kiadis Pharma Recent Developments
11.13 Mirati Therapeutics
11.13.1 Mirati Therapeutics Company Details
11.13.2 Mirati Therapeutics Business Overview
11.13.3 Mirati Therapeutics Myelodysplastic Syndrome Introduction
11.13.4 Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.13.5 Mirati Therapeutics Recent Developments
11.14 Astex
11.14.1 Astex Company Details
11.14.2 Astex Business Overview
11.14.3 Astex Myelodysplastic Syndrome Introduction
11.14.4 Astex Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.14.5 Astex Recent Developments
11.15 Celator Pharmaceuticals
11.15.1 Celator Pharmaceuticals Company Details
11.15.2 Celator Pharmaceuticals Business Overview
11.15.3 Celator Pharmaceuticals Myelodysplastic Syndrome Introduction
11.15.4 Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.15.5 Celator Pharmaceuticals Recent Developments
11.16 Eli-lilly
11.16.1 Eli-lilly Company Details
11.16.2 Eli-lilly Business Overview
11.16.3 Eli-lilly Myelodysplastic Syndrome Introduction
11.16.4 Eli-lilly Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.16.5 Eli-lilly Recent Developments
11.17 Sunesis Pharmaceuticals
11.17.1 Sunesis Pharmaceuticals Company Details
11.17.2 Sunesis Pharmaceuticals Business Overview
11.17.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Introduction
11.17.4 Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.17.5 Sunesis Pharmaceuticals Recent Developments
11.18 Targazyme
11.18.1 Targazyme Company Details
11.18.2 Targazyme Business Overview
11.18.3 Targazyme Myelodysplastic Syndrome Introduction
11.18.4 Targazyme Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.18.5 Targazyme Recent Developments
11.19 Gamida Cell
11.19.1 Gamida Cell Company Details
11.19.2 Gamida Cell Business Overview
11.19.3 Gamida Cell Myelodysplastic Syndrome Introduction
11.19.4 Gamida Cell Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.19.5 Gamida Cell Recent Developments
11.20 GlaxoSmithKline
11.20.1 GlaxoSmithKline Company Details
11.20.2 GlaxoSmithKline Business Overview
11.20.3 GlaxoSmithKline Myelodysplastic Syndrome Introduction
11.20.4 GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.20.5 GlaxoSmithKline Recent Developments
11.21 Sumitomo Dainippon Pharma
11.21.1 Sumitomo Dainippon Pharma Company Details
11.21.2 Sumitomo Dainippon Pharma Business Overview
11.21.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Introduction
11.21.4 Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.21.5 Sumitomo Dainippon Pharma Recent Developments
11.22 TetraLogic Pharmaceuticals
11.22.1 TetraLogic Pharmaceuticals Company Details
11.22.2 TetraLogic Pharmaceuticals Business Overview
11.22.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Introduction
11.22.4 TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022)
11.22.5 TetraLogic Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Myelodysplastic Syndrome Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Alkylating Agents
Table 3. Key Players of Cytotoxic Antibiotics
Table 4. Key Players of Topoisomerase Inhibitors
Table 5. Key Players of Others
Table 6. Global Myelodysplastic Syndrome Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Myelodysplastic Syndrome Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Myelodysplastic Syndrome Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Myelodysplastic Syndrome Market Share by Region (2017-2022)
Table 10. Global Myelodysplastic Syndrome Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Myelodysplastic Syndrome Market Share by Region (2023-2028)
Table 12. Myelodysplastic Syndrome Market Trends
Table 13. Myelodysplastic Syndrome Market Drivers
Table 14. Myelodysplastic Syndrome Market Challenges
Table 15. Myelodysplastic Syndrome Market Restraints
Table 16. Global Myelodysplastic Syndrome Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Myelodysplastic Syndrome Revenue Share by Players (2017-2022)
Table 18. Global Top Myelodysplastic Syndrome by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2021)
Table 19. Ranking of Global Top Myelodysplastic Syndrome Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Myelodysplastic Syndrome Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Myelodysplastic Syndrome Product Solution and Service
Table 23. Date of Enter into Myelodysplastic Syndrome Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Myelodysplastic Syndrome Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Myelodysplastic Syndrome Revenue Market Share by Type (2017-2022)
Table 27. Global Myelodysplastic Syndrome Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Myelodysplastic Syndrome Revenue Market Share by Type (2023-2028)
Table 29. Global Myelodysplastic Syndrome Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Myelodysplastic Syndrome Revenue Share by Application (2017-2022)
Table 31. Global Myelodysplastic Syndrome Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Myelodysplastic Syndrome Revenue Share by Application (2023-2028)
Table 33. North America Myelodysplastic Syndrome Market Size by Type (2017-2022) & (US$ Million)
Table 34. North America Myelodysplastic Syndrome Market Size by Type (2023-2028) & (US$ Million)
Table 35. North America Myelodysplastic Syndrome Market Size by Application (2017-2022) & (US$ Million)
Table 36. North America Myelodysplastic Syndrome Market Size by Application (2023-2028) & (US$ Million)
Table 37. North America Myelodysplastic Syndrome Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Myelodysplastic Syndrome Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Myelodysplastic Syndrome Market Size by Type (2017-2022) & (US$ Million)
Table 40. Europe Myelodysplastic Syndrome Market Size by Type (2023-2028) & (US$ Million)
Table 41. Europe Myelodysplastic Syndrome Market Size by Application (2017-2022) & (US$ Million)
Table 42. Europe Myelodysplastic Syndrome Market Size by Application (2023-2028) & (US$ Million)
Table 43. Europe Myelodysplastic Syndrome Market Size by Country (2017-2022) & (US$ Million)
Table 44. Europe Myelodysplastic Syndrome Market Size by Country (2023-2028) & (US$ Million)
Table 45. Asia Pacific Myelodysplastic Syndrome Market Size by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Myelodysplastic Syndrome Market Size by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Myelodysplastic Syndrome Market Size by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Myelodysplastic Syndrome Market Size by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Myelodysplastic Syndrome Market Size by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Myelodysplastic Syndrome Market Size by Region (2023-2028) & (US$ Million)
Table 51. Latin America Myelodysplastic Syndrome Market Size by Type (2017-2022) & (US$ Million)
Table 52. Latin America Myelodysplastic Syndrome Market Size by Type (2023-2028) & (US$ Million)
Table 53. Latin America Myelodysplastic Syndrome Market Size by Application (2017-2022) & (US$ Million)
Table 54. Latin America Myelodysplastic Syndrome Market Size by Application (2023-2028) & (US$ Million)
Table 55. Latin America Myelodysplastic Syndrome Market Size by Country (2017-2022) & (US$ Million)
Table 56. Latin America Myelodysplastic Syndrome Market Size by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Myelodysplastic Syndrome Market Size by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Myelodysplastic Syndrome Market Size by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Myelodysplastic Syndrome Market Size by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Myelodysplastic Syndrome Market Size by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Myelodysplastic Syndrome Market Size by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Myelodysplastic Syndrome Market Size by Country (2023-2028) & (US$ Million)
Table 63. Celgene Company Details
Table 64. Celgene Business Overview
Table 65. Celgene Myelodysplastic Syndrome Product
Table 66. Celgene Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 67. Celgene Recent Developments
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Myelodysplastic Syndrome Product
Table 71. Novartis Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 72. Novartis Recent Developments
Table 73. Otsuka Company Details
Table 74. Otsuka Business Overview
Table 75. Otsuka Myelodysplastic Syndrome Product
Table 76. Otsuka Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 77. Otsuka Recent Developments
Table 78. Actinium Pharmaceuticals Company Details
Table 79. Actinium Pharmaceuticals Business Overview
Table 80. Actinium Pharmaceuticals Myelodysplastic Syndrome Product
Table 81. Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 82. Actinium Pharmaceuticals Recent Developments
Table 83. Acceleron Pharma Company Details
Table 84. Acceleron Pharma Business Overview
Table 85. Acceleron Pharma Myelodysplastic Syndrome Product
Table 86. Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 87. Acceleron Pharma Recent Developments
Table 88. Bellicum Pharmaceuticals Company Details
Table 89. Bellicum Pharmaceuticals Business Overview
Table 90. Bellicum Pharmaceuticals Myelodysplastic Syndrome Product
Table 91. Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 92. Bellicum Pharmaceuticals Recent Developments
Table 93. Cornerstone Pharmaceuticals Company Details
Table 94. Cornerstone Pharmaceuticals Business Overview
Table 95. Cornerstone Pharmaceuticals Myelodysplastic Syndrome Product
Table 96. Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 97. Cornerstone Pharmaceuticals Recent Developments
Table 98. CTI BioPharma Company Details
Table 99. CTI BioPharma Business Overview
Table 100. CTI BioPharma Myelodysplastic Syndrome Product
Table 101. CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 102. CTI BioPharma Recent Developments
Table 103. Onconova Therapeutics Company Details
Table 104. Onconova Therapeutics Business Overview
Table 105. Onconova Therapeutics Myelodysplastic Syndrome Product
Table 106. Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 107. Onconova Therapeutics Recent Developments
Table 108. Strategia Therapeutics Company Details
Table 109. Strategia Therapeutics Business Overview
Table 110. Strategia Therapeutics Myelodysplastic Syndrome Product
Table 111. Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 112. Strategia Therapeutics Recent Developments
Table 113. KaloBios Pharmaceuticals Company Details
Table 114. KaloBios Pharmaceuticals Business Overview
Table 115. KaloBios Pharmaceuticals Myelodysplastic Syndrome Product
Table 116. KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 117. KaloBios Pharmaceuticals Recent Developments
Table 118. Kiadis Pharma Company Details
Table 119. Kiadis Pharma Business Overview
Table 120. Kiadis Pharma Myelodysplastic Syndrome Product
Table 121. Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 122. Kiadis Pharma Recent Developments
Table 123. Mirati Therapeutics Company Details
Table 124. Mirati Therapeutics Business Overview
Table 125. Mirati Therapeutics Myelodysplastic Syndrome Product
Table 126. Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 127. Mirati Therapeutics Recent Developments
Table 128. Astex Company Details
Table 129. Astex Business Overview
Table 130. Astex Myelodysplastic Syndrome Product
Table 131. Astex Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 132. Astex Recent Developments
Table 133. Celator Pharmaceuticals Company Details
Table 134. Celator Pharmaceuticals Business Overview
Table 135. Celator Pharmaceuticals Myelodysplastic Syndrome Product
Table 136. Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 137. Celator Pharmaceuticals Recent Developments
Table 138. Eli-lilly Company Details
Table 139. Eli-lilly Business Overview
Table 140. Eli-lilly Myelodysplastic Syndrome Product
Table 141. Eli-lilly Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 142. Eli-lilly Recent Developments
Table 143. Sunesis Pharmaceuticals Company Details
Table 144. Sunesis Pharmaceuticals Business Overview
Table 145. Sunesis Pharmaceuticals Myelodysplastic Syndrome Product
Table 146. Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 147. Sunesis Pharmaceuticals Recent Developments
Table 148. Targazyme Company Details
Table 149. Targazyme Business Overview
Table 150. Targazyme Myelodysplastic Syndrome Product
Table 151. Targazyme Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 152. Targazyme Recent Developments
Table 153. Gamida Cell Company Details
Table 154. Gamida Cell Business Overview
Table 155. Gamida Cell Myelodysplastic Syndrome Product
Table 156. Gamida Cell Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 157. Gamida Cell Recent Developments
Table 158. GlaxoSmithKline Company Details
Table 159. GlaxoSmithKline Business Overview
Table 160. GlaxoSmithKline Myelodysplastic Syndrome Product
Table 161. GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 162. GlaxoSmithKline Recent Developments
Table 163. Sumitomo Dainippon Pharma Company Details
Table 164. Sumitomo Dainippon Pharma Business Overview
Table 165. Sumitomo Dainippon Pharma Myelodysplastic Syndrome Product
Table 166. Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 167. Sumitomo Dainippon Pharma Recent Developments
Table 168. TetraLogic Pharmaceuticals Company Details
Table 169. TetraLogic Pharmaceuticals Business Overview
Table 170. TetraLogic Pharmaceuticals Myelodysplastic Syndrome Product
Table 171. TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2017-2022) & (US$ Million)
Table 172. TetraLogic Pharmaceuticals Recent Developments
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Myelodysplastic Syndrome Market Share by Type: 2021 VS 2028
Figure 2. Alkylating Agents Features
Figure 3. Cytotoxic Antibiotics Features
Figure 4. Topoisomerase Inhibitors Features
Figure 5. Others Features
Figure 6. Global Myelodysplastic Syndrome Market Share by Application: 2021 VS 2028
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Myelodysplastic Syndrome Report Years Considered
Figure 10. Global Myelodysplastic Syndrome Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Myelodysplastic Syndrome Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Myelodysplastic Syndrome Market Share by Region: 2021 VS 2028
Figure 13. Global Myelodysplastic Syndrome Market Share by Players in 2021
Figure 14. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome Revenue in 2021
Figure 16. North America Myelodysplastic Syndrome Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Myelodysplastic Syndrome Market Size Market Share by Type (2017-2028)
Figure 18. North America Myelodysplastic Syndrome Market Size Market Share by Application (2017-2028)
Figure 19. North America Myelodysplastic Syndrome Market Size Share by Country (2017-2028)
Figure 20. United States Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Myelodysplastic Syndrome Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Myelodysplastic Syndrome Market Size Market Share by Type (2017-2028)
Figure 24. Europe Myelodysplastic Syndrome Market Size Market Share by Application (2017-2028)
Figure 25. Europe Myelodysplastic Syndrome Market Size Share by Country (2017-2028)
Figure 26. Germany Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Myelodysplastic Syndrome Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Myelodysplastic Syndrome Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Myelodysplastic Syndrome Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Myelodysplastic Syndrome Market Size Share by Region (2017-2028)
Figure 36. China Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures
Figure 42. Latin America Myelodysplastic Syndrome Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Myelodysplastic Syndrome Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Myelodysplastic Syndrome Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Myelodysplastic Syndrome Market Size Share by Country (2017-2028)
Figure 46. Mexico Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Myelodysplastic Syndrome Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Myelodysplastic Syndrome Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Myelodysplastic Syndrome Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Myelodysplastic Syndrome Market Size Share by Country (2017-2028)
Figure 52. Turkey Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Myelodysplastic Syndrome Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Celgene Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 56. Novartis Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 57. Otsuka Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 58. Actinium Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 59. Acceleron Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 60. Bellicum Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 61. Cornerstone Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 62. CTI BioPharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 63. Onconova Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 64. Strategia Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 65. KaloBios Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 66. Kiadis Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 67. Mirati Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 68. Astex Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 69. Celator Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 70. Eli-lilly Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 71. Sunesis Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 72. Targazyme Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 73. Gamida Cell Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 74. GlaxoSmithKline Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 75. Sumitomo Dainippon Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 76. TetraLogic Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2017-2022)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

Global Myelodysplastic Syndrome Market

Myelodysplastic Syndrome Market Insights and Forecast to 2028 with COVID-19 Impact Analysis

Published Date : May 2022

Category : Pharmaceutical & Healthcare

Report Id : QYR 9029

Publisher Name : QY Research

Price : $4900

No of Pages : 127

Choose License Type

TRUST ONLINE

GET IN TOUCH

Connect with us

Global Myelodysplastic Syndrome Market

Myelodysplastic Syndrome Market Insights and Forecast to 2028 with COVID-19 Impact Analysis

Published Date : May 2022

Category : Pharmaceutical & Healthcare

Report Id : QYR 9029

Publisher Name : QY Research

Price : $4900

No of Pages : 127

Choose License Type

Related Reports

GET IN TOUCH

Connect with us